Everything below concerns freeze-thaw cycle. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
The m value, or number of corrected amino acid changes per 100 residues, for the C1orf27 gene was graphed against the species divergence in millions of years. When compared to divergence graphs of fibrinogen and cytochrome C, it was determined that this gene closely resembles the evolutionary pattern observed in fibrinogen, suggesting a more rapid rate of evolution. M values for C1orf27 were calculated using the percentage of identity, when compared to humans, observed in the mRNA sequences of the orthologs using the formula derived from the Molecular Clock Hypothesis.
== Non-chromatographic processing methods == Other plasma processing methods exist, but generally do not provide the resolution or purity of chromatographic methods. Two-phase liquid extraction may be performed using polyethylene glycol (PEG)-phosphate Aqueous two-phase systems, with a PEG-rich top layer and a phosphate-rich bottom layer. Although this method is somewhat useful for protein recovery, it does not work as well for the recovery of other blood components. Membrane fractionation has the advantage of minimal protein loss yet high removal of pathological plasma components. This method incorporates processes such as thermofiltration and applying pulsate flow. The latest two-stage membrane system utilizes a high flow recirculation circuit that is effective for removal of LDL cholesterol. It may prove useful for patients that have clogged arteries and other cardiovascular problems involving cholesterol. Batch adsorption, e.g. onto ion exchange media, is only useful when dealing with smaller samples of plasma, typically 200 mL or less. Batch adsorption recovers the product in a larger volume of elution buffer than does column chromatography or frontal chromatography, and the resulting more dilute product requires concentration, typically on a membrane system, which can lead to loss of product by irreversible adsorption to the membrane.
McDivitt must have switched to the VOX setting somewhere around the time White was exiting the spacecraft, because at that point, for most of the EVA, neither he nor White responded either to the Hawaii CAPCOM, or to the Houston CAPCOM, Gus Grissom. Grissom tried to talk to Gemini 4 a total of 40 times in 13 minutes before he got a response. Tied to a tether, White floated out of the spacecraft, using a Hand-Held Maneuvering Unit (informally called a "zip gun") which expelled pressurized oxygen to provide thrust for controlling his travel. He went 4.6 meters (15 ft) out and began to experiment with maneuvering. He found it easy, especially the pitch and yaw, although he thought the roll would use too much gas. He maneuvered around the spacecraft while McDivitt took photographs. White enjoyed the experience, but exhausted the HHMU gas sooner than he would have liked. White was running up against two factors which constrained the time for his EVA: loss of signal from the Bermuda tracking station and crossing the solar terminator. The flight controllers were becoming increasingly frustrated with their inability to remind White of the time constraint, because they didn't want the first EVA to be performed in darkness or out of communication with Earth. Finally McDivitt decided to take his microphone off VOX:
== Treatment == While there currently is no cure for Donohue syndrome, treatments for those with the disease are tailored specifically to the symptoms present in each individual. It is often that a team of medical professionals will come together to treat a patient with this condition in their specific realm of practice such as pediatrics, endocrinology, and dermatology. Treatment will often address specific dysfunctions in the patient, such as skin defects, hormonal imbalances, and normal progression of child growth.
Progesterone is used as a medication. The hormone is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels. It may also be used alone to treat menopausal symptoms. Studies have shown that transdermal progesterone (skin patch) and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats, otherwise referred to as vasomotor symptoms or VMS. Progesterone is also used to support pregnancy and fertility and to treat gynecological disorders. Progesterone has been shown to prevent miscarriage in those with vaginal bleeding early in their current pregnancy and having a previous history of miscarriage. Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes.
Sources: en.wikipedia.org
=== Heart arrhythmia === Lidocaine is a common class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine preventive dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.
Biochanin A is an O-methylated isoflavone. It is a natural organic compound in the class of phytochemicals known as flavonoids. Biochanin A can be found in red clover in soy, in alfalfa sprouts, in peanuts, in chickpea (Cicer arietinum) and in other legumes. Biochanin A is classified as a phytoestrogen. It has also been found to be a weak inhibitor of fatty acid amide hydrolase in vitro.
Mkhedrioni relied on illegal sources of income (targeting gasoline supplies) and exploited connections with Moscow's Georgian underworld. Mkhedrioni members were often accused of criminal activity, extorting "protection money" from businesses in areas which they effectively controlled, operating roadblocks where drivers would be "fined", smuggling drugs and committing robberies. By 1991, the Mkhedrioni was claimed to have had about 1,000 fighters and 10,000 associate members – considerably more than the official state National Guard. Despite Gamsakhurdia and Ioseliani sharing a broadly similar nationalist outlook, the two men fell out badly shortly after Gamsakhurdia came to power in November 1990. In February 1991, Ioseliani was imprisoned without trial, along with many of his supporters, and the Mkhedrioni was banned. In August 1991, just after the Soviet coup attempt, Gamsakhurdia sacked Tengiz Kitovani, the commander of Georgia's National Guard, and his Prime Minister Tengiz Sigua resigned around the same time. Kitovani soon formed an anti-Gamsakhurdia alliance with Sigua and the imprisoned Ioseliani. In December 1991, Kitovani's supporters released Ioseliani from jail and launched a violent coup d'état against the Gamsakhurdia government in alliance with the Mkhedrioni. Intense gun battles took place in the streets of Tbilisi between the rebels and "Zviadists" holed up in the state parliament building during December 1991 – January 1992, which ended with Gamsakhurdia fleeing to the breakaway Russian republic of Chechnya. At least 100 people were killed in the fighting.
You can't field the ball deep. You have to get out in front of it." Remarked Bagwell, "I was basically being given a lesson from Ozzie Smith at first base during a pitching change. It's pretty cool." The next year, Bagwell hit .273, driving in 96 runs with 18 home runs. In 1993, the Astros improved to a third-place finish in the National League West division, and in mid-September, Bagwell was batting .320 with 20 home runs and 88 RBI. However, a pitch from the Philadelphia Phillies' Ben Rivera broke the fourth metacarpal bone in Bagwell's left hand, ending his season prematurely. It was the first of three successive seasons that ended early or was interrupted due to an incoming pitch breaking the same bone in that hand. His tendency to dip just before starting to swing made his hand more vulnerable to being hit by inside pitches. His .320 average was sixth in the NL. In February 1994, Bagwell and the Astros agreed to a one-year contract with a $2.4 million base salary (USD, $5.3 million today).
Sources: en.wikipedia.org
However, there has been criticism that sports such as football (soccer) and baseball are doing nothing about the issue, and letting athletes implicated in doping get away unpunished. Some commentators maintain that, as outright prevention of doping is an impossibility, all doping should be legalised. However, most disagree with this, pointing out the claimed harmful long-term effects of many doping agents. Opponents claim that with doping legal, all competitive athletes would be compelled to use drugs, and the net effect would be a level playing field but with widespread health consequences. A common rebuttal to this argument asserts that anti-doping efforts have been largely ineffective due to both testing limitations and lack of enforcement, and so sanctioned steroid use would not be markedly different from the situation already in existence. Another point of view is that doping could be legalized to some extent using a drug whitelist and medical counseling, such that medical safety is ensured, with all usage published. Under such a system, it is likely that athletes would attempt to cheat by exceeding official limits to try to gain an advantage; this could be considered conjecture as drug amounts do not always correlate linearly with performance gains.
Ford won an 36-seat majority in the 44th Ontario general election. Originally scheduled by election date laws to be held by June 4, 2026, Ford triggered an early provincial election, called a snap election, for February 27, 2025, after meeting with Ontario's lieutenant-governor.
GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS. GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders. The company was acquired by BioReference Laboratories in 2006 and subsequently by Sema4 in 2022, after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx. Since launching exome testing in 2011, the company has built GeneDx Infinity, a large and diverse rare disease dataset including more than one million clinically sequenced exomes and genomes, more than 2.5 million tests, and more than 8 million phenotypic datapoints. In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter. For full-year 2025, the company reported revenue of approximately $427 million.
The particular series of amino acids that form a protein is known as that protein's primary structure. This sequence is determined by the genetic makeup of the individual. It specifies the order of side-chain groups along the linear polypeptide "backbone". Proteins have two types of well-classified, frequently occurring elements of local structure defined by a particular pattern of hydrogen bonds along the backbone: alpha helix and beta sheet. Their number and arrangement is called the secondary structure of the protein. Alpha helices are regular spirals stabilized by hydrogen bonds between the backbone CO group (carbonyl) of one amino acid residue and the backbone NH group (amide) of the i+4 residue. The spiral has about 3.6 amino acids per turn, and the amino acid side chains stick out from the cylinder of the helix. Beta pleated sheets are formed by backbone hydrogen bonds between individual beta strands each of which is in an "extended", or fully stretched-out, conformation. The strands may lie parallel or antiparallel to each other, and the side-chain direction alternates above and below the sheet. Hemoglobin contains only helices, natural silk is formed of beta pleated sheets, and many enzymes have a pattern of alternating helices and beta-strands. The secondary-structure elements are connected by "loop" or "coil" regions of non-repetitive conformation, which are sometimes quite mobile or disordered but usually adopt a well-defined, stable arrangement. The overall, compact, 3D structure of a protein is termed its tertiary structure or its "fold".
==== Phenibut ==== Phenibut (Anvifen, Fenibut, Noofen) is an anxiolytic used in Russia. Phenibut is a GABAB receptor agonist, as well as an antagonist at α2δ subunit-containing voltage-dependent calcium channels (VDCCs), similarly to gabapentinoids like gabapentin and pregabalin. The medication is not approved by the FDA for use in the United States, but is sold online as a supplement.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.